Thrombopoietin (TPO) acting via its receptor Mpl is the major cytokine regulator of platelet number. To precisely define the role of specific hematopoietic cells in TPO dependent hematopoiesis, we generated mice that express the Mpl receptor normally on stem/progenitor cells but lack expression on megakaryocytes and platelets (Mpl PF4cre/PF4cre ). Mpl PF4cre/PF4cre mice displayed profound megakaryocytosis and thrombocytosis with a remarkable expansion of megakaryocyte-committed and multipotential progenitor cells, the latter displaying biological responses and a gene expression signature indicative of chronic TPO over-stimulation as the underlying causative mechanism, despite a normal circulating TPO level. Thus, TPO signaling in megakaryocytes is dispensable for platelet production; its key role in control of platelet number is via generation and stimulation of the bipotential megakaryocyte precursors. Nevertheless, Mpl expression on megakaryocytes and platelets is essential to prevent megakaryocytosis and myeloproliferation by restricting the amount of TPO available to stimulate the production of megakaryocytes from the progenitor cell pool.
Abstract:
Thrombopoietin (TPO) acting via its receptor Mpl is the major cytokine regulator of platelet number. To precisely define the role of specific hematopoietic cells in TPO dependent hematopoiesis, we generated mice that express the Mpl receptor normally on stem/progenitor cells but lack expression on megakaryocytes and platelets (Mpl PF4cre/PF4cre ). Mpl PF4cre/PF4cre mice displayed profound megakaryocytosis and thrombocytosis with a remarkable expansion of megakaryocyte-committed and multipotential progenitor cells, the latter displaying biological responses and a gene expression signature indicative of chronic TPO over-stimulation as the underlying causative mechanism, despite a normal circulating TPO level. Thus, TPO signaling in megakaryocytes is dispensable for platelet production; its key role in control of platelet number is via generation and stimulation of the bipotential megakaryocyte precursors. Nevertheless, Mpl expression on megakaryocytes and platelets is essential to prevent megakaryocytosis and myeloproliferation by restricting the amount of TPO available to stimulate the production of megakaryocytes from the progenitor cell pool.
Significance statement:
Blood platelets, the small circulating cells that co-ordinate hemostasis, are produced by specialized bone marrow cells called megakaryocytes. The cytokine thrombopoietin (TPO) is a key regulator of platelet production acting via its specific cell receptor, Mpl. Via genetic modification of the Mpl allele in mice, we precisely define the bone marrow cells that express Mpl and, by genetically removing Mpl from megakaryocytes and platelets, we show TPO signaling via Mpl is not required in megakaryocytes for their expansion, maturation or platelet production. Rather, Mpl expression on megakaryocytes is essential for regulating TPO availability in the bone marrow microenvironment to prevent myeloproliferation, a model we suggest is important for human disease. Thrombopoietin (TPO) is the principal hematopoietic cytokine that regulates platelet production at steady state and is required for rapid responses to platelet loss. TPO acts by binding to a specific cell surface receptor, Mpl, leading to receptor dimerization, activation of intracellular signal transduction pathways and responses of target cells. Mice lacking TPO or Mpl are severely thrombocytopenic and deficient in megakaryocytes and their progenitor cells, a phenotype consistent with a role for TPO in maintaining appropriate megakaryocyte numbers in vivo. In addition to its role in megakaryopoiesis, TPO is also an indispensible regulator of hematopoietic stem cells (HSC), essential for maintenance of quiescence and self-renewal (1) .
TPO is produced primarily in the liver (2) and upon binding to the Mpl receptor on target cells is internalised and degraded. The prevailing model posits that circulating TPO concentration is inversely proportional to the "Mpl-mass" contributed by the total number of megakaryocytes and platelets. In normal individuals this model describes an effective feedback system to regulate TPOdriven megakaryocyte and platelet production according to need. The reciprocal relationship between platelet number and circulating TPO level is clearly evident in bone marrow transplant patients (1) , and the key role of the TPO receptor is illustrated by the elevated circulating TPO in Mpl -/mice (3) and the modest elevation of platelet counts in transgenic mice expressing low levels of Mpl (4, 5) . However, the relationship between circulating TPO concentration and peripheral platelet counts is not always conserved in pathological states of thrombocytosis and thrombocytopenia (6) (7) (8) (9) suggesting that a simple relationship between megakaryocyte and platelet "Mpl-mass", circulating TPO concentration and the degree of stimulation of megakaryopoiesis may not always hold.
While expression of Mpl on megakaryocytes and platelets contributes to regulation of available TPO, the role of direct TPO stimulation of megakaryocytes for effective platelet production is unclear. Administration of TPO in vivo or stimulation of bone marrow in vitro elevates megakaryocyte numbers and increases mean DNA ploidy (10, 11) and the thrombocytopenia in TPO -/mice is accompanied by reduced megakaryocyte ploidy (12) . However, while exposure of megakaryocytes to TPO stimulates intracellular signaling (13) , in vitro studies suggesting direct action of TPO on megakaryocytes to increase DNA ploidy, promote cytoplasmic maturation or to stimulate proplatelet production (14) (15) (16) are balanced by reports that TPO is dispensable for these megakaryocyte functions (15, (17) (18) (19) .
To comprehensively define Mpl-expressing stem and progenitor cell populations in vivo and resolve the specific requirements for Mpl expression in megakaryocytes and platelets for platelet production and feedback control of TPO levels, we generated a novel mouse strain in which green fluorescent protein (GFP) is expressed from the Mpl locus and, when crossed to Platelet Factor 4(PF4)cre transgenic mice (20) , specifically lacks Mpl expression in megakaryocytes and platelets.
Results
A targeting vector was constructed for generation, via homologous recombination in embryonic stem cells, of a modified Mpl allele (Mpl fl/fl ) designed to retain Mpl expression and provide a green fluorescent protein (GFP) reporter for transcriptional activity of the Mpl locus. The inclusion of loxP sites allowed for cre recombinase-mediated deletion of the GFP reporter as well as exons 11 and 12, resulting in a null allele ( Fig. 1A and SI Materials and Methods). PF4-cre transgenic mice (20) have been reported to allow specific and efficient deletion of conditional alleles in megakaryocytes and platelets. To verify the activity and cell-type specificity of PF4-cre mice, particularly in view of a recent report of activity in HSCs (21), we crossed PF4-cre mice to mice in which enhanced yellow fluorescent protein (EYFP) is expressed in a cre-dependent manner (Rosa26EYFP (22) ). While, as expected, EYFP was not expressed in the absence of cre recombinase, in Rosa26EYFP PF4Cre mice EYFP was expressed in megakaryocytes and platelets, consistent with previous reports (20) and not in erythroid, lymphoid or myeloid cells ("SI Appendix, Fig. S1A") . Megakaryocyte formation progresses from a series of TPO-responsive bipotential erythroid-megakaryocyte progenitors (23) . EYFP was not expressed in Lineage-negative Sca-1 + Kit + (LSK) bone marrow cells, the population containing stem and primitive multipotential progenitor cells, nor in any progenitor cell fraction tested, including the BEMP and CD150 + CD9 hi megakaryocyte/erythroid-restricted bipotential megakaryocyte-erythroid progenitor population and CFU-E erythroid progenitor population ("SI Appendix, Table S1 , Fig. S1B ,C"). EYFP expression was observed in a proportion of cells in a previously uncharacterised CD150 + Fc R + population (Lin -Sca-1 -Kit + CD150 + IL7R -Fc RII/III + Endoglin lo CD9 hi , "SI Appendix, Fig. S1B ,C") that comprised ~ 0.01% of the bone marrow ("SI Appendix, Fig. S2A ") and which demonstrated potent erythro-megakaryocytic potential in vitro and in vivo ("SI Appendix, Fig. S2B ,C"). We conclude that the CD150 + Fc R + fraction includes megakaryocyte precursors downstream from the previously characterised CD150 + CD9 + fraction, revealed by the onset of PF4 promoter activity that, given the lack of YFP expression in CFU-E in Rosa26EYFP PF4Cre mice, may define a megakaryocyterestricted precursor within the bipotential CD150 + Fc R + fraction. Thus cre-dependent recombination using the PF4-cre transgenic mouse was restricted to late megakaryocyte progenitors, megakaryocytes and platelets and absent in other progenitor cells and hematopoietic lineages. mice was entirely consistent with the activity of PF4-cre defined in Rosa26EYFP PF4Cre mice.
Mpl expression is absent in megakaryocytes and platelets, but retained in megakaryocyte progenitor and stem cells in Mpl

Mpl PF4cre/PF4cre mice develop a marked thrombocytosis and megakaryocytosis
While Mpl PF4cre/PF4cre mice were healthy and displayed no outward abnormalities, analysis of peripheral blood (Table 1) Table 2 ). The profound thrombocytosis in Mpl PF4cre/PF4cre was not accompanied by significant extension in platelet lifespan ("SI Appendix, Fig. S4B") . Together, these data suggest that the thrombocytosis in Mpl PF4cre/PF4cre mice is caused primarily by excess production of megakaryocytes and their progenitors.
Mpl PF4cre/PF4cre mice have perturbed stem and progenitor cell compartments and develop features of myeloproliferation
In addition to excess numbers of megakaryocyte progenitor cells, the total number of myeloid progenitor cells in the bone marrow and spleen of Mpl PF4cre/PF4cre mice was also significantly elevated, with a particular increase in the number of blast colony-forming cells, a phenotype also observed in the bone marrow of TPO Tg mice ( Table 2 ). HSC and myeloid progenitor cell populations were analysed by flow cytometry, with particular emphasis on cells with megakaryocyte potential. Mpl PF4cre/PF4cre mice displayed a two-to four-fold increase in bone marrow LSK cells, Lin -cKit + Sca1myeloid progenitors, pre-granulocyte-macrophage (PreGM) progenitors, GM progenitors (GMP) and CD150 + CD9 hi and CD150 + Fc R + bipotential erythroidmegakaryocyte progenitor populations, with a reduction in erythroid progenitors (preCFU-E and CFU-E) when compared to Mpl +/+ and/or Mpl fl/fl controls ( Fig. 3 , "SI Appendix, Fig. S5") . This was similar to the effects caused by chronic excessive in vivo TPO stimulation (TPO Tg , Fig. 3 , "SI Appendix, Fig. S5" and (23) ), but was significantly more marked in Mpl PF4cre/PF4cre mice.
Blast cell colonies, which represent primitive multi-potential pre-progenitor cells (26) predominantly derived from the LSK population (27, 28) were picked from primary cultures and replated. Blast cell colonies from Mpl PF4cre/PF4cre mice had a sigificantly increased propensity to formation of secondary colonies, an effect also evident in TPO Tg mice, particularly secondary blast cell and megakaryocyte colonies ("SI Appendix, Fig. S6") , demonstrating a greater in vitro capacity for pre-progenitor cell self-renewal and secondary colony formation when compared to Mpl fl/fl controls. This provides evidence at the single cell level that Mpl PF4cre/PF4cre multipotential preprogenitor cells, like those in TPO Tg mice, have characteristics of chronic excessive TPO exposure. 4A) . Surprisingly, the circulating TPO level in Mpl PF4cre/PF4cre mice, was not significantly different from Mpl fl/fl controls. Transcription of TPO in the liver, the major site of TPO production, was unaltered in Mpl PF4cre/PF4cre mice (Fig. 4B ). This finding implies that Mpl-expressing LSK and megakaryocyte/erythroid progenitor cells in Mpl PF4cre/PF4cre mice, which are expanded significantly in number, clear circulating TPO to levels observed in Mpl-replete mice, even in the absence of clearance by megakaryocytes and platelets. 29), "SI Appendix, Table S2 , and SI Materials and Methods"). Signature genes of TPO Tg LSKs and Mpl -/-LSKs were defined as those that were significantly differentially expressed in a positive direction by pair-wise comparison to wild-type LSKs ("SI Appendix, Table S3 , S4"). Rotational gene set tests were then performed using ROAST (30) with the "TPO over-stimulation" gene signature from TPO Tg LSKs and the "TPO starvation" gene signature from Mpl -/-LSKs. This analysis revealed that genes associated with TPO overstimulation in TPO Tg LSKs were strongly correlated with upregulated genes in Mpl PF4cre/PF4cre LSKs whereas the gene signature associated with TPO starvation in Mpl -/-LSKs was associated with downregulated genes in Mpl PF4cre/PF4cre LSKs (Fig. 4C ). This data confirms at a genetic level that Mpl expressing stem and progenitor cells in Mpl PF4cre/PF4cre mice were exposed to excessive TPO stimulation, explaining the behaviour of their pre-progenitor blast colonies at the single cell level and the mechanistic basis for the myeloproliferation, megakaryocytosis and thrombocytosis obverved in Mpl PF4cre/PF4cre mice.
Stem and progenitor cells expressing Mpl are responsible for TPO clearance in Mpl
Gene expression profiling of Mpl
Human CD34 + stem and progenitor cells demonstrate a Mpl PF4cre/PF4cre LSK gene expression signature
Megakaryocytes and platelets in human myeloproliferative neoplasms have been shown to express reduced levels of MPL (31, 32) . To explore the possibility that reduced MPL expression on megakaryocytes and platelets in human disease might contribute to the myeloproliferative phenotype via a mechanism analagous to the excessive TPO stimulation of stem and progenitor cells evident in the Mpl PF4cre/PF4cre model, we compared the gene expression signature of Mpl PF4cre/PF4cre LSK cells ("SI Appendix, Table S2" 
Discussion
While it has been established TPO signaling is required for maintaining steady state platelet numbers and response to crises requiring rapid platelet production, the precise cellular mechanisms by which TPO actions are achieved remained largely undefined. Our results definitively establish that 1) Mpl expression on megakaryocytes is dispensable for high level platelet production and megakaryocyte maturation, 2) the primary mechanism by which TPO signaling stimulates thrombopoiesis is via Mpl-expressing hematopoietic progenitors, and 3) Mpl receptor on megakaryocytes and platelets acts predominantly, if not solely to regulate, via internalization and degradation, the amount of TPO available to hematopoietic stem and progenitor cell populations ( Fig. 5 ).
Regarding the role of Mpl expression on megakaryocytes, while increased megakaryocyte ploidy has been associated with high TPO activity and the converse has been observed in TPO/Mpldeficient mouse models (3, (10) (11) (12) , a shift to higher ploidy megakaryocytes accompanied marked thrombocytosis in Mpl PF4cre/PF4cre mice was observed despite the absence of Mpl expression in megakaryocytes. Thus, thrombopoiesis and the development of high DNA ploidy in megakaryocytes is independent of TPO signaling in these cells; the latter likely reflecting alternative mechanisms associated with states of increased megakaryocyte production. A role for TPO in sensitizing platelets to specific activators (34) Increasingly, evidence has suggested a close physical relationship between megakaryocytes and bone marrow stem/progenitor cell niches. Imaging studies have identified megakaryocytes colocalising with CD150 + CD48 -Lin -HSCs adjacent to sinusoidal endothelium (35) as well as in close proximity to Nestin + mesenchymal stem cells, which form a significant functional component of the HSC niche (36) .
The importance of TPO as a multi-functional regulator of hematopoiesis was highlighted. Chronic TPO overstimulation in Mpl PF4cre/PF4cre and TPO Tg mice resulted in excess numbers of primitive multipotential pre-progenitor blast colonies that are principally derived from LSK cells, a population that expresses Mpl. The increased propensity of pre-progenitor cells to self-renew and to produce increased numbers progenitors of multiple myeloid lineages with chronic TPO overstimulation provide a mechanistic rationale for the effectiveness of the TPO mimetic agent eltrombopag in the restoration of bone marrow cellularity and multi-lineage haemopoiesis in patients with severe refractory aplastic anemia (37) . Additionally, megakaryocyte lineage skewing of pre-progenitor cells derived from Mpl PF4cre/PF4cre mice suggests excessive TPO stimulation may also act during these earlier stages in the hematopoietic hierarchy for megakaryocyte lineage specification. In more differentiated progenitors, identification of Mpl receptor expression on bipotential progenitor populations that were expanded in Mpl PF4cre/PF4cre mice and were associated with megakaryocytosis and a relative paucity of erythroid precursors, confirms our previous findings (23) . Thus, bipotenital erythro-megakaryocytic progenitors express Mpl and are critical effector cells of TPO-dependent thrombopoiesis that are driven to differentiate into megakaryocytes in response to TPO, and which under conditions of excessive TPO stimulation, are skewed toward megakaryocytopoiesis at the expense of erythropoiesis. Despite increased number of diverse myeloid progenitor cells in Mpl PF4cre/PF4cre mice, the number of circulating white blood cells was not consistently elevated, suggesting the contribution of other regulatory mechanisms in control of mature granulocyte and macrophage number.
Finally, the demonstration that the chronic TPO stimulation gene expression signature in LSK cells of Mpl PF4cre/PF4cre mice was also evident in the gene expression changes in human bone marrow CD34 + cells from patients with essential thrombocythemia, provides an important potential explanation for the observation that abnormally low expression of MPL in platelets and megakaryocytes of human patients with myeloproliferative disorders is associated with thrombocytosis (31, 32) . Our data support a model that such disorders may be in part underpinned by insufficient MPL mass within the platelet/megakaryocyte pool resulting in increased TPO stimulation of the MPL expressing stem and progenitor cells similar to that observed in Mpl PF4cre/PF4cre mice.
Materials and Methods:
Mice were analysed at age 7-12 weeks. TPO Tg (3) and Mpl -/- (24) Table S2 ") can distinguish between CD34 + bone marrow cells of patients with essential thromboocythemia from controls ((33) GEO database GSE9827, P = 1.48x10 -2 ). P value derived from rotational gene set testing using ROAST with the Mpl PF4cre/PF4cre LSK gene signature weighted by log fold-change (see "SI Appendix, Table S2 , see also Fig. S7 and SI Materials and Methods"). Numbers of colonies from 25,000 unfractionated bone marrow cells or 50,000 spleen cells cultured in stem-cell factor (SCF, 100 ng/mL), interleukin-3 (IL3, 10ng/mL) and erythropoietin (EPO, 2U/mL) with the type and number of colonies scored after 7 days. G; granulocyte, GM; granulocytemacrophage, M; macrophage, Eo; eosinophil, Meg; megakaryocyte. * = P < 0.03 compared to Mpl +/+ by Student's unpaired two-tailed t-test.
Figure Legends
